Abstract
The tumoral clone of Waldenström's macroglobulinemia (WM) shows a wide morphological heterogeneity, which ranges from B lymphocytes (BL) to plasma cells (PC). By means of genome-wide expression profiling we have been able to identify genes exclusively deregulated in BL and PC from WM, but with a similar expression pattern in their corresponding cell counterparts from chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), as well as normal individuals. The differentially expressed genes have important functions in B-cell differentiation and oncogenesis. Thus, two of the genes downregulated in WM-BL were IL4R, which plays a relevant role in CLL B-cell survival, and BACH2, which participates in the development of class-switched PC. Interestingly, one of the upregulated genes in WM-BL was IL6. A set of four genes was able to discriminate clonal BL from WM and CLL: LEF1 (WNT/β-catenin pathway), MARCKS, ATXN1 and FMOD. We also found deregulation of genes involved in plasma cell differentiation such as PAX5, which was overexpressed in WM-PC, and IRF4 and BLIMP1, which were underexpressed. In addition, three of the target genes activated by PAX5 – CD79, BLNK and SYK – were upregulated in WM-PC. In summary, these results indicate that both PC and BL from WM are genetically different from the MM and CLL cell counterpart.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M . Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: 214–226.
Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110–115.
San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez ML et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 187–195.
Ghobrial IM, Gertz MA, Fonseca R . Waldenstrom macroglobulinaemia. Lancet Oncol 2003; 4: 679–685.
Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R . 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 153–155.
Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100: 2996–3001.
Chng WJ, Schop R, Price-Troska T, Ghobrial I, Kay N, Jelinek DF et al. Gene expression profiling of Waldenstrom's macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755–2763.
Gutiérrez NC, López-Pérez R, Hernéndez JM, Isidro I, González B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402–409.
Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP . Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
Eisen MB, Spellman PT, Brown PO, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.
Borg I, Groenen PM . Modern Multidimensional Scaling: Theory and Applications. Springer Verlag: New York, 1997.
Tusher VG, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116–5121.
Smyth GK . Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
Reiner A, Yekutieli D, Benjamini Y . Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368–375.
Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567–6572.
Shaulian E, Karin M . AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390–2400.
Hock BD, Haring LF, Steinkasserer A, Taylor KG, Patton WN, McKenzie JL . The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res 2004; 28: 237–241.
Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 2000; 5: 311–320.
Shapiro-Shelef M, Calame K . Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 2004; 16: 226–234.
Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD . Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 2004; 17: 1217–1222.
Shapiro-Shelef M, Calame K . Regulation of plasma-cell development. Nat Rev Immunol 2005; 5: 230–242.
Calame KL, Lin KI, Tunyaplin C . Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003; 21: 205–230.
Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 3584–3592.
Till KJ, Lin K, Zuzel M, Cawley JC . The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002; 99: 2977–2984.
Wong S, Fulcher D . Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 2004; 45: 2491–2496.
Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature 2005; 434: 843–850.
Qiang YW, Endo Y, Rubin JS, Rudikoff S . Wnt signaling in B-cell neoplasia. Oncogene 2003; 22: 1536–1545.
Howe D, Bromidge T . Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk Res 2006; 30: 29–32.
Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118–3123.
Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL . Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol 2001; 66: 1–6.
Kay NE, Pittner BT . IL-4 biology: impact on normal and leukemic CLL B cells. Leuk Lymphoma 2003; 44: 897–903.
Sakane-Ishikawa E, Nakatsuka S, Tomita Y, Fujita S, Nakamichi I, Takakuwa T et al. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J Clin Oncol 2005; 23: 8012–8017.
Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, Sakoda E et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 2004; 429: 566–571.
Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005; 105: 1566–1573.
Mikaelsson E, nesh-Manesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 2005; 105: 4828–4835.
Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA . Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002; 62: 4398–4405.
Cooper D, Lindberg FP, Gamble JR, Brown EJ, Vadas MA . Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc Natl Acad Sci USA 1995; 92: 3978–3982.
Mateo V, Brown EJ, Biron G, Rubio M, Fischer A, Deist FL et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 2002; 100: 2882–2890.
Katayama Y, Sakai A, Oue N, Asaoku H, Otsuki T, Shiomomura T et al. A possible role for the loss of CD27–CD70 interaction in myelomagenesis. Br J Haematol 2003; 120: 223–234.
Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA 1997; 94: 6346–6351.
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494.
Liang Y, Tedder TF . Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001; 72: 119–127.
Martínez N, Camacho FI, Algara P, Rodríguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226–8232.
Wynn TA . IL-13 effector functions. Annu Rev Immunol 2003; 21: 425–456.
Acknowledgements
We to thank Mark Anderson from the University Technology Transfer Office, and Isabel Isidro and Teresa Prieto for technical assistance. This study was partially supported by Spanish Myeloma Network Program (G03/136), ‘Ministerio de Ciencia y Tecnología’ grant (SAF 04/06587) and ‘Junta de Castilla y León’ grant (106/A/06).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Gutiérrez, N., Ocio, E., de las Rivas, J. et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21, 541–549 (2007). https://doi.org/10.1038/sj.leu.2404520
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404520
Keywords
This article is cited by
-
An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma
Clinical and Experimental Medicine (2024)
-
Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies
Biomarker Research (2021)
-
IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma
Oncogene (2021)
-
MARCKS regulates tonic and chronic active B cell receptor signaling
Leukemia (2019)
-
How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
Current Oncology Reports (2019)